Five-year data from Coopervision’s long-running, paediatric myopia management study has revealed encouraging results for its MiSight one-day lens for slowing myopia progression.
Part one of the study quantified three-year effectiveness of MiSight one-day compared with an equivalent single vision one-day lens in slowing the rate of progression of juvenile-onset myopia. Part two of the study involved the original control group being refitted with MiSight one-day, at three years, and tracked separately to compare myopia progression rates between the two matched populations with different treatment history.
Two years on, the progression rates among the original control group - after showing a significant reduction in year four following refitting - matched the children who’d been wearing MiSight one-day for the duration of the study in spherical equivalent refractive error (0.17D) and axial length (0.07mm). The company also reported, “vision performance remained excellent among both groups… (and) there were minimal adverse events.”
Research director Paul Chamberlain said the results suggest myopia progression with MiSight one-day lenses is more dependent on the patient’s age than their baseline myopia or length of time under treatment. “This information can help practitioners as they consider treating slightly older kids than studied in part one of the trial.”
In other news, Coopervision said it’s on track to donate up to US$500,000 from its MiSight one-day sales to Our Children’s Vision by the end of 2020.
